The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States

References

• Bartlett DL, Chu E. Can metastatic colorectal cancer be cured? Oncology 2012;26:266-75
   PubMed Web of Science ®Google Scholar
• Kemeny N, Garay CA, Gurtler J, et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 2004;22:4753-61
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program (http://www.seer.cancer.gov) Research Data (1975-2011), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released May 2014, based on the November 2013 submission. Accessed February 1, 2015
   Google Scholar
• Engstrom PF, Arnoletti JP, Benson AB, et al. NCCN clinical practice guidelines in oncology: colon cancer. J Natl Compr Canc Netw 2009;7:778-831
   PubMed Web of Science ®Google Scholar
• Hess GP, Wang PF, Quach D, et al. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. J Oncol Pract 2010;6:301-7
   PubMedGoogle Scholar
• Seal BS, Sullivan SD, Ramsey SD, et al. Systemic therapy for colorectal cancer: patterns of chemotherapy and biologic therapy use in nationally representative US claims database. BioDrugs 2014;28:229-36
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30:3499-506
   PubMed Web of Science ®Google Scholar
• Hohla F, Winder T, Greil R, et al. Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. World J Gastroenterol 2014;20:6102-12
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006;33(5 Suppl 10):S26-S34
   PubMed Web of Science ®Google Scholar
• Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96:1788-95
   PubMed Web of Science ®Google Scholar
• Tachi T, Teramachi H, Tanaka K, et al. The impact of outpatient chemotherapy-related adverse events on the quality of life of breast cancer patients. PLoS One 2015;10:e0124169.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7
   PubMed Web of Science ®Google Scholar
• Maughan TS, James RD, Kerr DJ, et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002;359:1555-63
   PubMed Web of Science ®Google Scholar
• Fu A, Zhou Z, Wang S, et al. Hospital costs of adverse events in patients with metastatic colorectal cancer. J Cancer Ther 2013;4:153-8
   Google Scholar
• Niraula S, Amir E, Vera-Badillo F, et al. Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. J Clin Oncol 2014;32:3634-42
   PubMed Web of Science ®Google Scholar
• Burudpakdee C, Zhao Z, Munakata J, et al. Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies. J Med Econ 2012;15:371-7
   PubMedGoogle Scholar
• Overbeek JA, Zhao Z, van Herk-Sukel MP, et al. Costs of hospital events in patients with metastatic colorectal cancer. J Med Econ 2011;14:656-61
   PubMedGoogle Scholar
• Hurvitz S, Guerin A, Brammer M, et al. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting. Oncologist 2014;19:901-8
   PubMed Web of Science ®Google Scholar
• Stuart EA. Matching methods for causal inference: A review and a look forward. Stat Sci 2010;25:1-21
   PubMed Web of Science ®Google Scholar
• Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-51
   PubMed Web of Science ®Google Scholar
• Fu A, Zhou Z, Gao S, et al. Comorbid conditions in patients with metastatic colorectal cancer. World J Oncol 2011;2:225-31
   PubMedGoogle Scholar
• Overbeek JA, Zhao Z, Van Herk-Sukel MP, et al. Cardiovascular comorbidities among patients with metastatic colorectal cancer. J Cancer Ther Res 2012;1:4. http://dx.doi.org/10.7243/2049-7962-1-4
   Google Scholar
• Amersi F, Agustin M, Ko CY. Colorectal cancer: epidemiology, risk factors, and health services. Clin Colon Rectal Surg 2005;18:133-40
   PubMedGoogle Scholar
• Ording AG, Horvath-Puho E, Erichsen R, et al. Five-year mortality in colorectal cancer patients with ulcerative colitis or Crohn's disease: a nationwide population-based cohort study. Inflamm Bowel Dis 2013;19:800-5
   PubMed Web of Science ®Google Scholar
• The Consumer Price Index (CPI). US Department of Labor, Bureau of Labor Statistics; 2016. http://www.bls.gov/cpi/. Accessed November 2015
   Google Scholar
• Andrews DWK, Buckinsky M. A three-step method for choosing the number of bootstrap repetitions. Econometrica 2000;68:23-51
   Web of Science ®Google Scholar
• Davidson R, MacKinnon J. Bootstrap tests: how many bootstraps? Econ Rev 2000;19:55-68
   Google Scholar
• Bendell JC, Bekaii-Saab TS, Cohn AL, et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist 2012;17:1486-95
   PubMed Web of Science ®Google Scholar
• Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065-75
   PubMed Web of Science ®Google Scholar
• Liou SY, Stephens JM, Carpiuc KT, et al. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig 2007;27:381-96
   PubMed Web of Science ®Google Scholar
• Weycker D, Li X, Edelsberg J, et al. Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract 2014;001492; published online on December 9, 2014
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66
   PubMed Web of Science ®Google Scholar
• Klastersky JA, Paesmans M. Treatment of febrile neutropenia is expensive: prevention is the answer. Onkologie 2011;34:226-8
   PubMedGoogle Scholar
• Donohue R. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia. Oncol Nurs Forum 2006;33:347-52
   PubMed Web of Science ®Google Scholar
• Demetri GD. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 2001;84(Suppl 1):31-7
   PubMed Web of Science ®Google Scholar
• Marchetti M, Barosi G. Clinical and economic impact of epoetins in cancer care. Pharmacoeconomics 2004;22:1029-45
   PubMed Web of Science ®Google Scholar